CN103301373B - Pharmaceutical composition for treating postpartum perineal mucosal lesions - Google Patents
Pharmaceutical composition for treating postpartum perineal mucosal lesions Download PDFInfo
- Publication number
- CN103301373B CN103301373B CN201310269334.4A CN201310269334A CN103301373B CN 103301373 B CN103301373 B CN 103301373B CN 201310269334 A CN201310269334 A CN 201310269334A CN 103301373 B CN103301373 B CN 103301373B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- brown
- parched
- mucosal lesions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 230000009854 mucosal lesion Effects 0.000 title abstract 4
- 239000003814 drug Substances 0.000 claims abstract description 39
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 241000242759 Actiniaria Species 0.000 claims abstract description 14
- 241001506940 Alpinia japonica Species 0.000 claims abstract description 14
- 210000004877 mucosa Anatomy 0.000 claims description 25
- 241001604597 Pyrestini Species 0.000 claims description 19
- 210000002640 perineum Anatomy 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 239000010271 massa medicata fermentata Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 7
- 244000144730 Amygdalus persica Species 0.000 abstract description 2
- 241001465251 Ephedra sinica Species 0.000 abstract description 2
- 241000331528 Chlorophytum capense Species 0.000 abstract 1
- 244000223060 Erythrina herbacea Species 0.000 abstract 1
- 235000005280 Erythrina herbacea Nutrition 0.000 abstract 1
- 241000488974 Loranthus Species 0.000 abstract 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 230000003071 parasitic effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- 239000008280 blood Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000012286 potassium permanganate Substances 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241001083548 Anemone Species 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000167696 Prenanthes Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000008350 Pruritus Vulvae Diseases 0.000 description 2
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 235000011446 Amygdalus persica Nutrition 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 241000723237 Ephedra intermedia Species 0.000 description 1
- 241000218670 Ephedraceae Species 0.000 description 1
- 244000070010 Erythrina variegata Species 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 241000931143 Gleditsia sinensis Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 241000221040 Loranthaceae Species 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000172774 Ranunculus ternatus Species 0.000 description 1
- 241000316341 Taxillus chinensis Species 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating postpartum perineal mucosal lesions, so as to solve the problem of treatment of postpartum perineal mucosal lesions. The pharmaceutical composition is characterized by being prepared from the following crude drugs: bark of himalayan coralbean, smallflower bracketplant herb, bobbin, alpinia japonica, parasitic loranthus, radix ranunculi ternate, dark malt, burnt medicated leaven, Chinese ephedra root, spina gleditsiae, peach gum, and rhizome anemones altaicae. The clinical test shows that the pharmaceutical composition has the characteristics of good curative effect and high safety on treatment of the postpartum perineal mucosal lesions, and is worthy of clinical application and popularization.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of pharmaceutical composition for the treatment of postpartum perineum mucosa infection.
Background technology
Puerperal uterus, cervix uteri, vagina, perineum can produce a series of change because hormonal readiness declines rapidly.For perineum, during childbirth, due to fetus extruding vagina collar extension.Usually cause perineum hyperemia, edema, or have laceration in various degree, fade away in after this 7 days.Meanwhile, perineal position is also because of pleat minimizing around, and intravaginal mucosa is smooth, and mucosal defense power reduces the symptoms such as easy secondary pruritus vulvae, vaginal dryness.In general, at short notice, vaginal mucosa is not easy to return to pregravidic situation completely, and only after stopping is breast-feeded, menstrual onset, ovarian function is normal, and under functions of hormones, vaginal mucosa just recovers normal gradually.
Current is for symptom for postpartum perineum mucosa infection mostly, and as given 50% magnesium sulfate dressing to alleviate edema, 1:5000 potassium permanganate liquid rinses the soak of cooperation 0.2% metronidazole solution to protect from infection.But in fact, because the basic pathology of morbidity is: puerperal, estrogen level declined rapidly, caused the relative atrophy of vaginal wall, mucosa is thinning, and in epithelial cell, glycogen content reduces, and intravaginal Ph value rises, local resistance reduces, and pathogenic bacterium are easily invaded breeding and cause and inflammation.And magnesium sulfate, potassium permanganate liquid flushing liquor are also a kind of stimulations for mucosa, early stage myxedema problem can be solved, but unfavorable on the contrary to long-term prognosis.
Chinese medicine perineum Wet-dressing agent is many, but be mostly for Women of Childbearing Age, many containing the medicine except noxious dampness such as Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae in prescription, and the cause of postpartum perineum mucosa infection mainly mucosa is thinning causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more, causes aggravation.And said medicine bitter cold is unfavorable for postpartum recovery.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and the pharmaceutical composition of the little treatment postpartum perineum mucosa infection of side effect.
The technical scheme that the present invention solves its technical problem is: a kind of pharmaceutical composition for the treatment of postpartum perineum mucosa infection, it is characterized in that being prepared from by the crude drug of following weight proportion: Cortex erythrinae 10 ~ 30 parts, Herba Chlorophyti Laxi 6 ~ 12 parts, go back 3 ~ 10 parts, bobbin, Alpinia japonica (Thunb.) Miq. 6 ~ 12 parts, Herba Taxilli 3 ~ 10 parts, Radix Ranunculi Ternati 6 ~ 12 parts, Fructus Hordei Germinatus (parched to brown) 6 ~ 12 parts, Massa Medicata Fermentata (parched to brown) 6 ~ 12 parts, Radix Ephedrae 6 ~ 12 parts, Spina Gleditsiae 1 ~ 5 part, gumshiraz 3 ~ 10 parts, Rhizoma Anemones Altaicae 10 ~ 25 parts.
Chinese medicine of the present invention is prepared from by the raw material of following optimum weight part proportioning: Cortex erythrinae 20 parts, Herba Chlorophyti Laxi 10 parts, go back 6 parts, bobbin, Alpinia japonica (Thunb.) Miq. 10 parts, Herba Taxilli 6 parts, Radix Ranunculi Ternati 10 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Massa Medicata Fermentata (parched to brown) 10 parts, Radix Ephedrae 10 parts, Spina Gleditsiae 2 parts, gumshiraz 6 parts, Rhizoma Anemones Altaicae 20 parts.
Wherein said: Cortex erythrinae is bark or the root bark of pulse family Erythrinae Arborescentis Erythrina indica Lam..Nature and flavor are bitter, flat.Return liver, kidney channel.Merit can wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Herba Chlorophyti Laxi is herb or the root of feverfew Prenanthes henryi Dunn Prenanthes henryi Dunn.Bitter in the mouth; Cold in nature.Merit can heat-clearing and toxic substances removing; Dissipating blood stasis stops blooding.
Also bobbin is the fruit of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Sweet in the mouth; Cold in nature.Merit can tonify deficiency subduing the wind syndrome.Main dizzy; Pupil; Wind syndrome of head is had a headache; Weak breath consumption of essence; Early whitening of beard and hair.
Alpinia japonica (Thunb.) Miq., is Zingiberaceae Alpinia plants Alpinia japonica (Thunb.) Miq. Alpinia japonica Miq., is used as medicine with root stock.Nature and flavor are pungent, warm.Return lung, spleen, Liver Channel.Merit can dispelling wind and removing obstruction in the collateral, regulating QI to relieve pain.
Herba Taxilli, for Herba Taxilli is the dry stem and branch with leaf of Loranthaceae plant Herba Taxilli Taxillus chinensis (DC.) Danser.Nature and flavor bitter, sweet, flat.Return liver, kidney channel.Merit can invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive unit.
Radix Ranunculi Ternati is the dried root of ranunculaceae plant Seynuns Kugelann Ranunculus ternatus Thunb..Nature and flavor sweet, acrid, warm.Return liver, lung meridian.Merit can eliminating stagnation, detumescence.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. is through drying of germinateing, fries to burnt brown according to frying method, cooling, sieve dedust bits.Nature and flavor are sweet, flat.Return spleen, stomach warp.Merit can promote qi circulation digestion promoting, and spleen benefiting and stimulating the appetite, moves back newborn relieving distension.
Massa Medicata Fermentata (parched to brown), for the medicines such as Herba polygoni hydropiperis, Herba Artemisiae Annuae, Semen Armeniacae Amarum add flour or wheat bran mixed after, through the herbal leaven of fermentation, fry to burnt brown according to frying method.Nature and flavor sweet, acrid, warm.Enter spleen, stomach warp.Merit can invigorating the spleen and regulating the stomach, helps digestion in adjusting.
Radix Ephedrae is the dry root and rhizome of Ephedraceae plant plait Herba Ephedrae Ephedra sinica Stapf or epheday intermedia Ephedra intermedia Schrenk et C. A. Mey..Nature and flavor are sweet, flat.GUIXIN, lung meridian.Merit can hidroschesis.
Spina Gleditsiae is the dry Spina jujubae of leguminous plant Fructus Gleditsia Gleditsia sinensis Lam..Nature and flavor are pungent, temperature.Return liver, stomach warp.Merit can be subsided a swelling poison holding, evacuation of pus, parasite killing.
Gumshiraz is rosaceous plant Fructus Persicae Prunus persica (L.) Batsch, the resin that trunk flows out.Nature and flavor are bitter, flat.Merit can be invigorated blood circulation, and QI invigorating is quenched the thirst.
Rhizoma Anemones Altaicae, is Ranunculaceae thimbleweed anemone altaica Anemone altaica Mey., is used as medicine with root stock.Nature and flavor are pungent, temperature.Merit can causing resuscitation with aromatic drugs, reduces phlegm, calms the nerves.
Composition principle: postpartum perineum mucosa infection often reduces because of ovarioestrogen level, and vaginal wall mucosa is thinning, in epithelial cell, glycogen content reduces, and intravaginal Ph value rises, and local resistance reduces, and pathogenic bacterium are easily invaded breeding and cause and inflammation.Cardinal symptom is that vaginal secretions increases and pruritus vulvae, burning sensation.The colpitic suppository of current Chinese traditional treatment, Wet-dressing agent are many, but be mostly for Women of Childbearing Age, many containing the medicine except noxious dampness such as Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae in prescription, and the cause of postpartum perineum mucosa infection mainly mucosa is thinning causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more, causes aggravation.The object of the invention is to avoid using dispelling the damp pathogen with drugs of bitter in taste and cold in nature medicine, and reduce from estrogen level, vaginal wall atrophy, mucosa this pathological change angle thinning is started with, and reaches the object of " treatment of disease must aim at its pathogenesis ".
Compared with prior art, the present invention has following characteristics:
1, prescription is unique, avoids using dispelling the damp pathogen with drugs of bitter in taste and cold in nature antipruritic agent: get Cortex erythrinae in side, go back bobbin for monarch, the Cortex erythrinae dosage recorded in " China's book on Chinese herbal medicine " is: " for oral administration: to decoct soup, 6-12g "; Inventor to test in proof heavy dose of Cortex erythrinae (10 ~ 30g) and can recover by specific promotion vaginal wall mucosa, and goes back bobbin and have similar plants estrogen action, but this act as two-ways regulation, can not produce the low differentiation of estrogen excessive stimulation reproductive system cell;
2, characteristic of the present invention is also balance and restriction: records Cortex erythrinae in 1. " must joining book on Chinese herbal medicine ": " insufficiency of blood heated person forbid ", but puerperal resembling often with deficiency of YIN-blood, and now use Cortex erythrinae, then have and fear its hematozemia and cause yin asthenia generating intrinsic heat to occur; Therefore add Herba Chlorophyti Laxi and go back bobbin, also bobbin merit can train base by tonify deficiency, and can prevent Cortex erythrinae from consuming cloudy blood and liver-wind stirring up internally, and Herba Chlorophyti Laxi bitter in the mouth is cold in nature, utilize on the one hand it coldly to prevent heated, its merit can dissipating blood stasis hemostasis on the other hand, has out entire merit in blood system, prevent Cortex erythrinae to wander away dynamic blood, also can not affect Cortex erythrinae works orderly effect simultaneously; 2. in we, the use of Rhizoma Anemones Altaicae is: a causing resuscitation with aromatic drugs and benefaction, two Yin Yang balancings, and to balance the bitter cold of our invasion by pathogenic cold medicine of a cold nature thing, inventor's clinical research finds that Rhizoma Anemones Altaicae is activated yang and do not consume the moon in addition, is suitable for using puerperal; In prescription of the present invention, the application characteristic of Rhizoma Anemones Altaicae is: measure larger (consumption in " Chinese Pharmacopoeia " is 1.5-6g), so too disperse for preventing, gets again Radix Ephedrae convergence assistant system;
3, supplementary drug thing is fewer but better: get Alpinia japonica (Thunb.) Miq. assistant in side and help Herba Chlorophyti Laxi, it act as giving treatment in accordance with the tendency of pathological change, and heat conduction is descending; Radix Ranunculi Ternati and Herba Chlorophyti Laxi are arranged in pairs or groups the effect of removing toxic substances, eliminating stagnation, pain relieving; Herba Taxilli assistant helps goes back bobbin vital base and primordial QI consolidating; Gumshiraz is invigorated blood circulation, and contributes to drag residence in mucomembranous surface, penetration enhancement;
4, inventor's clinical research finds, Fructus Hordei Germinatus (parched to brown), the external of Massa Medicata Fermentata (parched to brown) decoct can promote local mucous membrane blood circulation;
5, Spina Gleditsiae is supplementary drug thing, and the consumption recorded in " China's book on Chinese herbal medicine " is: " for oral administration: to decoct soup, 6 ~ 12g ", and the present inventor's experimental study finds, gets low dose of Spina Gleditsiae decocting liquid and can improve in vitro vaginal mucosa cytoactive;
6, the homogeneous medicine multiple-effect of institute's thing of getting it filled in side, contributes to reducing medicament categories and consumption, does not increase local excitation;
7, medicine material consumption of the present invention is groped to sum up to draw through inventor in a large number, and each raw material dosage is for all to have good curative effect in following weight parts scope.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Cortex erythrinae 20g, Herba Chlorophyti Laxi 10g, go back bobbin 6g, Alpinia japonica (Thunb.) Miq. 10g, Herba Taxilli 6g, Radix Ranunculi Ternati 10g, Fructus Hordei Germinatus (parched to brown) 10g, Massa Medicata Fermentata (parched to brown) 10g, Radix Ephedrae 10g, Spina Gleditsiae 2g, gumshiraz 6g, Rhizoma Anemones Altaicae 20g.
The preparation method of embodiment 1 is: by Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Alpinia japonica (Thunb.) Miq., Herba Taxilli, Radix Ranunculi Ternati, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Spina Gleditsiae, gumshiraz, the decoction of Rhizoma Anemones Altaicae mixing and water adding, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges soak, once a day.
Embodiment 2, crude drug weight proportion: Cortex erythrinae 10 parts, Herba Chlorophyti Laxi 6 parts, go back 3 parts, bobbin, Alpinia japonica (Thunb.) Miq. 6 parts, Herba Taxilli 3 parts, Radix Ranunculi Ternati 6 parts, Fructus Hordei Germinatus (parched to brown) 6 parts, Massa Medicata Fermentata (parched to brown) 6 parts, Radix Ephedrae 6 parts, Spina Gleditsiae 1 part, gumshiraz 3 parts, Rhizoma Anemones Altaicae 10 parts.
Embodiment 3, crude drug weight proportion: Cortex erythrinae 20 parts, Herba Chlorophyti Laxi 10 parts, go back 6 parts, bobbin, Alpinia japonica (Thunb.) Miq. 10 parts, Herba Taxilli 6 parts, Radix Ranunculi Ternati 10 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Massa Medicata Fermentata (parched to brown) 10 parts, Radix Ephedrae 10 parts, Spina Gleditsiae 2 parts, gumshiraz 6 parts, Rhizoma Anemones Altaicae 20 parts.
Embodiment 4, crude drug weight proportion: Cortex erythrinae 30 parts, Herba Chlorophyti Laxi 12 parts, go back 10 parts, bobbin, Alpinia japonica (Thunb.) Miq. 12 parts, Herba Taxilli 10 parts, Radix Ranunculi Ternati 12 parts, Fructus Hordei Germinatus (parched to brown) 12 parts, Massa Medicata Fermentata (parched to brown) 12 parts, Radix Ephedrae 12 parts, Spina Gleditsiae 5 parts, gumshiraz 10 parts, Rhizoma Anemones Altaicae 25 parts.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) by Cortex erythrinae, Radix Ranunculi Ternati, Radix Ephedrae coarse powder distilling under reduced pressure extraction volatile oil respectively, and mixing for standby use after collecting, medicinal residues mixing for standby use;
(2) will go back bobbin decompression decoction 2 times, each 30min, collecting decoction, filters after leaving standstill, obtains filtrate for subsequent use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Rhizoma Anemones Altaicae and step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, filter after leaving standstill, obtain filtrate for subsequent use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to obtain dry extract;
(5) spray in step 4 gained dry extract by gained volatile oil in step 1, mixing, cross 100 mesh sieves, subpackage forms.
The efficient combination of said medicine, coordinates mutually, effectively reach the object for the treatment of postpartum perineum mucosa infection, and side effect is less.The above results is clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1 data and method.
1.1.1 case selection: in January, 2011 ~ 2013 are diagnosed as postpartum perineum mucosa infection 148 example year June, are full-term normal delivery primipara.Get rid of trichomonal vaginitis, monilial vaginitis, urine is cultivated negative.
1.1.2 diagnostic criteria: with reference to " obstetrics and gynecology " (the 5th edition), all cases is all clarified a diagnosis according to medical history, gynecologial examination.Symptom is perineum pruritus, xerosis vulae, the pale or flushing of vaginal mucosa or have little petechia, and vaginal health scoring <15 divides.
1.1.3 divide into groups: be divided into matched group 48 example, soak group 50 example and powder group 50 example.Compare in age, the state of an illness, the course of disease before three groups of patient treatments, no significant difference (P>0.05), has comparability.
1.2 method.
1.2.1 Therapeutic Method: matched group adopts 1:5000 potassium permanganate liquid to rinse the soak of cooperation 0.2% metronidazole solution, 1 time/d.Soak group with gained decoct soak in the embodiment of the present invention 1,1 time/d.Powder group is blown deposited with gained powder pudendum and intravaginal in the embodiment of the present invention 3,1 time/d.It within 7 days, is a course for the treatment of.
1.2.2 observation index: conventional inquiry medical history before and after medication, and according to vaginal health point system (VHS) scoring, determine that symptom improves situation.
1.2.3 criterion of therapeutical effect: with reference to " obstetrics and gynecology ", recovery from illness: clinical symptoms, sign disappear; Effective: clinical symptoms, sign turn for the better by and large; Effective: clinical symptoms, sign alleviate; Invalid: clinical symptoms, sign are unchanged.
1.2.4 statistical analysis: SPSS 16.0 carries out statistical analysis.Vaginal health scoring single index adopts nonparametric statistics.Measurement data t checks, enumeration data χ
2inspection.
2 results.
2.1 vaginal symptoms improve situations: after medication 3d, matched group 27.08%(13/48) patient, and soak group and all case pruritus of vagina of powder group, drying, pain symptom all start the improvement that obtains in various degree.Gynecologial examination vaginal wall elasticity increases, and fold is deepened, and pale, the flushing in surface and bleeding are clearly better.According to vaginal health standards of grading, vaginal health scoring is the summation of elasticity, wettability, pH, mucosa, secretions 5 project score values.Before soak group patient medication, scoring is 9.29 ± 2.36, and average of marking after medication 7d is 14.27 ± 2.82.Before powder group patient medication, scoring is 10.62 ± 2.72, and average of marking after medication 7d is 17.27 ± 2.28.Compare before and after medication, after two groups of patient treatments, vaginal health scoring is all obviously increased (P<0.05).
2.2 3 groups of Comprehensive Clinical comparitive study: after medication 7d, matched group cure rate, obvious effective rate, effective percentage, inefficiency are respectively 31.25%, 43.75%, 18.75%, 6.25%; The cure rate of soak group, obvious effective rate, effective percentage, inefficiency are respectively 56.00%, 34.00%, 10.00%, 0.00%; The cure rate of powder group, obvious effective rate, effective percentage, inefficiency are respectively 70.00%, 18.00%, 12.00%, 0.00%.Three groups are compared, and the cure rate of soak group and powder group, total effective rate are apparently higher than matched group (P<0.05), and the cure rate of powder group is apparently higher than soak group (P<0.05).
2.3 adverse reaction rates: three groups of patients all do not occur obvious adverse reaction.
3. conclusion.
This result of study shows, and soak group of the present invention and powder group treatment postpartum perineum mucosa infection total effective rate are 100%, and the cure rate of powder group is higher than soak group.Have the advantage that untoward reaction is comparatively light, safety is higher.
Claims (1)
1. treat a pharmaceutical composition for postpartum perineum mucosa infection, it is characterized in that being prepared from by the crude drug of following weight proportion: Cortex erythrinae 20 parts, Herba Chlorophyti Laxi 10 parts, go back 6 parts, bobbin, Alpinia japonica (Thunb.) Miq. 10 parts, Herba Taxilli 6 parts, Radix Ranunculi Ternati 10 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Massa Medicata Fermentata (parched to brown) 10 parts, Radix Ephedrae 10 parts, Spina Gleditsiae 2 parts, gumshiraz 6 parts, Rhizoma Anemones Altaicae 20 parts; The occupation mode of described pharmaceutical composition is that powder pudendum and intravaginal are blown deposited.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310269334.4A CN103301373B (en) | 2013-07-01 | 2013-07-01 | Pharmaceutical composition for treating postpartum perineal mucosal lesions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310269334.4A CN103301373B (en) | 2013-07-01 | 2013-07-01 | Pharmaceutical composition for treating postpartum perineal mucosal lesions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103301373A CN103301373A (en) | 2013-09-18 |
| CN103301373B true CN103301373B (en) | 2015-04-08 |
Family
ID=49127379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310269334.4A Expired - Fee Related CN103301373B (en) | 2013-07-01 | 2013-07-01 | Pharmaceutical composition for treating postpartum perineal mucosal lesions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103301373B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316270B (en) * | 2013-07-01 | 2015-03-18 | 丁霄雁 | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion |
| CN103721083B (en) * | 2014-01-13 | 2015-11-18 | 姜霞 | A kind of pharmaceutical composition for gestational vulvareczema |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1148205C (en) * | 2001-01-10 | 2004-05-05 | 刘从清 | Yinkang lotion |
| CN100409859C (en) * | 2006-05-15 | 2008-08-13 | 贵州柏强制药有限公司 | Fuyanjing membrane for treating gynecological inflammation and preparation method thereof |
| CN101406558A (en) * | 2007-12-18 | 2009-04-15 | 展翼 | Gynaecologic washing lotion for preventing and treating colpitis |
| CN102018754B (en) * | 2009-09-11 | 2013-04-24 | 李强 | Vaginal effervescent tablet and making process thereof |
-
2013
- 2013-07-01 CN CN201310269334.4A patent/CN103301373B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103301373A (en) | 2013-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN102836409B (en) | Traditional Chinese medicine for treating postpartum lochiorrhea and preparation method | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN103301373B (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN104940718A (en) | Pharmaceutical composition for treatment of chronic cholecystitis and preparation method thereof | |
| CN104721553A (en) | Oral medicine for treating allergic rhinitis | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN103285300B (en) | Medicinal composition for treating stress incontinence | |
| CN103301374B (en) | Pharmaceutical composition for treating postpartum non-specificity vaginitis | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN101366878A (en) | Traditional Chinese medicine for female acyesis and aphoria and preparation method thereof | |
| CN103341094B (en) | Preparation method of powder for treating vulva squamous epithelial cell hyperplasia | |
| CN104887950A (en) | Mastitis treatment traditional Chinese medicine compound | |
| CN104857414A (en) | Medicine composite for treating chronic simple rhinitis | |
| CN117752753B (en) | Traditional Chinese medicine composition for nourishing yin, activating blood and preventing miscarriage | |
| CN112675264B (en) | Composition for treating psoriasis, preparation method and application thereof | |
| CN103316258B (en) | Medicine composition for treating infantile vaginitis | |
| CN103301354B (en) | Preparation method of powder for treating infantile vaginitis | |
| CN105169111A (en) | Traditional Chinese medicine composition for treating chronic urticaria and application of traditional Chinese medicine composition | |
| CN105232997A (en) | Chinese herba preparation used for treating endometritis and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHU YUEYING Free format text: FORMER OWNER: DING XIAOYAN Effective date: 20150306 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhu Yueying Inventor after: Bi Yuzhen Inventor after: Jiang Chunjie Inventor after: Wu Jun Inventor after: Feng Tao Inventor before: Ding Xiaoyan Inventor before: Feng Tao Inventor before: Geng Hui |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 255036 ZIBO, SHANDONG PROVINCE TO: 255036 JINAN, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: DING XIAOYAN FENG TAO GENG HUI TO: ZHU YUEYING BI YUZHEN JIANG CHUNJIE WU JUN FENG TAO |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150306 Address after: 255036, Shandong, Ji'nan Province, Zhangqiu City, Zhangqiu City, Shandong province senior officials Zhai Zhai Township Health Center Applicant after: Zhu Yueying Address before: 255036 Zibo Central Hospital, Shandong, Shandong, China, Zhangdian, No. 54, No. Applicant before: Ding Xiaoyan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150408 Termination date: 20150701 |
|
| EXPY | Termination of patent right or utility model |